| Bioactivity | MK-1084 is a selective KRAS G12C inhibitor that is currently in Phase I clinical trial (NCT05067283). MK-1084 exhibits anticancer activity and can be used either alone or in combination with pembrolizumab (HY-P9902) for cancer research[1]. |
| CAS | 2641216-67-1 |
| Formula | C32H31ClF2N6O4 |
| Molar Mass | 637.08 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rojas C, et al. 663P Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC[J]. Annals of Oncology, 2023, 34: S466-S467. |
MK-1084
CAS: 2641216-67-1 F: C32H31ClF2N6O4 W: 637.08
MK-1084 is a selectiveKRAS G12Cinhibitor that is currently in Phase I clinical trial (NCT05067283). MK-1084 exhibits ant
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.